Structure, Function, and Biology of the Enterococcus faecalis Cytolysin by Van Tyne, Daria et al.
 
Structure, Function, and Biology of the Enterococcus faecalis
Cytolysin
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Van Tyne, Daria, Melissa J. Martin, and Michael S. Gilmore.
2013. “Structure, Function, and Biology of the Enterococcus
faecalis Cytolysin.” Toxins 5 (5): 895-911.
doi:10.3390/toxins5050895.
http://dx.doi.org/10.3390/toxins5050895.
Published Version doi:10.3390/toxins5050895
Accessed February 19, 2015 2:00:08 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717548
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAToxins 2013, 5, 895-911; doi:10.3390/toxins5050895 
 
toxins 
ISSN 2072-6651 
www.mdpi.com/journal/toxins 
Review 
Structure, Function, and Biology of the Enterococcus faecalis 
Cytolysin  
Daria Van Tyne, Melissa J. Martin and Michael S. Gilmore * 
Department of Ophthalmology and Department of Microbiology and Immunobiology, Harvard 
Medical School, Massachusetts Eye and Ear Infirmary, 243 Charles St., Boston, MA 02114, USA 
*  Author to whom correspondence should be addressed;  
E-Mail: michael_gilmore@meei.harvard.edu; Tel.: +1-617-573-3845. 
Received: 25 March 2013; in revised form: 22 April 2013 / Accepted: 23 April 2013 /  
Published: 29 April 2013 
 
Abstract:  Enterococcus faecalis is a Gram-positive commensal member of the gut 
microbiota of a wide range of organisms. With the advent of antibiotic therapy, it has 
emerged as a multidrug resistant, hospital-acquired pathogen. Highly virulent strains of  
E. faecalis express a pore-forming exotoxin, called cytolysin, which lyses both bacterial 
and eukaryotic cells in response to quorum signals. Originally described in the 1930s,  
the cytolysin is a member of a large class of lanthionine-containing bacteriocins produced 
by Gram-positive bacteria. While the cytolysin shares some core features with other 
lantibiotics, it possesses unique characteristics as well. The current understanding of 
cytolysin biosynthesis, structure/function relationships, and contribution to the biology of 
E. faecalis are reviewed, and opportunities for using emerging technologies to advance this 
understanding are discussed.  
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1. Introduction: The Enterococci as Emergent Hospital Pathogens 
Enterococci are ancient members of the animal microbiome that are believed to date back at least to 
the last common ancestor of mammals, reptiles, birds and insects in the early Devonian period,   
412 million years ago [1]. These bacteria thrive in the nutrient-rich, oxygen-depleted environment of 
the intestinal tract, and at least in part because of shedding from animal hosts, are readily found in the 
environment [2]. They are core members of the commensal intestinal microbiota, which is densely 
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colonized with up to 10
11 bacterial cells/gram feces [3,4]. Enterococci are the predominant Gram-positive 
cocci found within this niche, and in humans they can be isolated at concentrations of 10
5 to 10
7 
CFU/gram feces [5,6]. Bacteriophage induction in response to environmental cues is emerging as one 
strategy for enterococcal colonization and control in the intestinal ecosystem [7]. The presence of 
enterococci in the complex ecology of the gastrointestinal tract provides an ample reservoir where 
genetic exchange and selection can occur. 
Enteroccoci are low-GC, Gram-positive, non-sporulating, facultative anaerobes that currently rank 
among the most prevalent multidrug resistant hospital pathogens worldwide [1]. They are the third 
most commonly isolated healthcare pathogen [8], and are capable of causing a variety of infections 
including endocarditis, sepsis, surgical wound infections, and urinary tract infections [5,9,10]. The 
genus Enterococcus consists of over 40 ecologically diverse species [5,11], yet more than 90 percent of 
enterococcal infections are caused by two species: E. faecalis and E. faecium [8,10,12]. The genomes 
of multidrug resistant enterococci consist of more than 25 percent mobile elements, which reflect a 
rampant accumulation of drug resistance elements and virulence factors [13]. Many enterococcal 
mobile elements are transferable by conjugation on pheromone-responsive plasmids, broad host range 
conjugative plasmids, or conjugative transposons [14,15]. The production of sex pheromone peptides 
by plasmid-free strains allows conjugative pheromone-responsive plasmids to transfer at rates as high 
as 10
−3 to 10
−1 per donor cell [16], efficiently disseminating virulence and antibiotic resistance genes 
between strains [17,18].  
The horizontal transfer of mobile elements has contributed much to the evolving fitness of 
enterococci in hospital settings [11,18]. Since the 1960’s, hospital-associated enterococcal infections 
have become increasingly antibiotic resistant [19]. Antibiotic treatment results in a loss of protection 
from host colonization as well as reduced microbial species diversity among the intestinal microbiota. 
This provides an opportunity for drug resistant enterococci to invade the intestinal niche and 
proliferate uncontrollably [3,20]. Horizontally acquired antimicrobial resistances were first described 
in the 1970’s [21]. Analysis of an outbreak of multidrug resistant enterococcal bacteremia in the   
mid-1980s determined that half of all isolates were from the same hemolytic clone [22]. Subsequently, 
the first vancomycin-resistant clinical isolate of E. faecalis, strain V583, was isolated in the United 
States from the bloodstream of an infected patient [23]. Hospital endemic and epidemic multidrug 
resistant enterococcal infection rates have since continued to increase worldwide [24–26]. 
Enterococcal disease was first described in detail in the late 19th century, when an abundant   
Gram-positive diploccocus was isolated from patients with intestinal diseases that was similar to an 
organism isolated from healthy patients [27]. This saprophytic microbe, named ‘Enterocoque’, was 
initially difficult to culture, most likely due to now-appreciated nutrient auxotrophies [27,28]. 
Pathogenicity was reproduced in rabbit and mouse models, in which inoculation lead to severe 
infection and fatality [27]. A further report from Thiercelin [29] described translocation of the bacteria 
from the gastrointestinal tract to the bloodstream, resulting in septicemia. At about the same time, 
MacCallum and Hastings described a death due to enterococcal infection causing acute endocarditis [30]. 
Originally designated as Micrococcus zymogenes, the bacterium isolated from the blood and cardiac 
vegetations of the patient was used to intraperitoneally infected mice, rabbits and dogs, and was found 
to recapitulate the same endocarditis symptoms [30], satisfying Koch’s Postulates and establishing 
Enterococcus as the cause of the patient’s death. Toxins 2013, 5  897 
 
 
The observation that some E. faecalis strains produced zones of hemolysis on blood agar plates led 
to the first comprehensive study of the hemolysin molecule [31]. Subsequently, hemolysis was found 
to be caused by a unique toxin, now termed cytolysin, as it lyses a broad range of target cells including 
both Gram-positive bacteria and eukaryotic cells [31–35]. The cytolysin is now known to make a large 
contribution to the pathogenicity of E. faecalis [36,37]. 
2. Cytolysin and Toxicity of Enterococcal Infections 
The cytolysin toxin of E. faecalis, termed a “streptolysin” since it was produced by Lancefield 
group D Streptococcus and caused a zone of hemolysis on blood agar,  was first experimentally 
characterized in 1934 [31]. E. faecalis (then called Streptococcus faecalis) was first considered to be 
pseudo-hemolytic, as hemolytic activity could rarely be detected in liquid broth but was readily seen 
on blood agar [31]. A gradient of erythrocyte susceptibilities, depending on species of origin, was 
observed, with human, horse, dog, rabbit and mouse erythrocytes being susceptible, and sheep and 
goose erythrocytes being resistant to lysis. A horse flesh infusion was derived that supported 
production of cytolysin in liquid culture, allowing for its characterization as a heat-labile, oxygen 
stable molecule (in contrast to the family of thiol-activated, cholesterol dependent cytolysins produced 
by other Gram-positive bacteria) [31]. In addition, hemolysin-producing enterococcal strains   
were observed to have bacteriocin activity against streptococcal strains and other Gram-positive 
bacteria [38–40]. The bactericidal and hemolytic phenotypes were experimentally characterized to be 
due to a single molecule. Brock et al. [39] showed that the hemolytic and bactericidal activities were 
both lost after UV irradiation and that restoration of one activity reestablished the other. The molecule 
was termed E. faecalis cytolysin to reflect the dual bactericidal and cytolytic activities exhibited [41].  
The association of cytolysin expression and increased toxicity of enterococcal infections has   
been studied in multiple animal models, as well as in clinical outcomes (Table 1). Ike and Clewell  
first described enhanced virulence due to cytolysin expression in the mouse through dose-dependent 
intraperitoneal injection with E. faecalis strains harboring the plasmid pAD1, which encodes   
cytolysin [42]. After 7 days of infection with cytolysin negative strains (3 × 10
9 CFU) all mice 
survived, while mice injected with cytolysin positive strains (≥10
9 CFU) died within 4–5 h [43]. 
Subsequently, cytolysin positive variants were shown to lyse mouse erythrocytes, macrophages and 
polymorphonuclear neutrophils [44]. Toxicity due to cytolysin was also determined in a rabbit 
endocarditis model, whereby cytolysin and aggregation substance positive strains were lethal in   
55 percent of infections, versus 15 percent in animals infected with only aggregation substance 
positive strains [45]. In rabbit endophthalmitis, cytolytic strains readily destroyed organ function   
and were untreatable, compared to isogenic, non-cytolytic strains [46,47]. When C. elegans is fed on  
lawns of cytolysin positive E. faecalis, death occurs faster than when fed on isogenic non-cytolytic  
bacteria [48].  
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Table 1. Contribution of the E. faecalis cytolysin to virulence. 
Setting  Effect of Cytolysin  Reference 
Human bacteremia  Cytolysin makes infection five times more acutely lethal  [22] 
Rabbit endophthalmitis  Cytolysin makes infection acutely destructive to retina and 
other ocular structures, and refractory to antibiotic treatment 
[46,47,49] 
Mouse intraperitoneal 
infection 
Cytolysin makes infection approximately one hundred times 
more acutely lethal 
[42,50] 
Rabbit endocarditis  Cytolysin makes infection acutely lethal in synergy with 
aggregation substance 
[45] 
C. elegans ingestion  Cytolysin makes infection acutely lethal following ingestion  [48] 
The cytolysin has also been shown to be associated with increased toxicity in human infection.  
A retrospective study analyzed 190 clinical E. faecalis isolates and found that 45 percent of isolates 
were cytolysin positive. Furthermore, even after controlling for treatment modality and drug resistance, 
patients infected with cytolytic E. faecalis were at a five-fold increased risk of an acutely terminal 
outcome (death within three weeks of diagnosis) compared to patients infected with non-cytolytic 
strains [22]. E. faecalis can cause a severe postoperative endophthalmitis, and cytolytic strains have 
been found to be common in these infections [51]. Epidemiological studies from Japan found   
that 60 percent of E. faecalis isolates analyzed from two hospitals were cytolysin positive [52]. 
Another study found that hemolysis was common to all clinical enterococci isolates investigated 
(which is not typical), while only six percent of food isolates were hemolytic [53]. In addition to 
causing increased toxicity of infection, the bacteriocin activity of the cytolysin may well be an 
important colonization factor of E. faecalis in the intestine, prior to establishment of infection at 
another sterile body site. In vitro experiments showed that cytolytic strains can outcompete 
bacteriocin-sensitive enterococci and other Gram-positive bacteria in liquid broth culture [39]. 
Cytolysin was also observed to be produced by E. faecalis isolated from nine out of 31 healthy infants 
in Norway [54]. 
Although a broad understanding of the genetics and biosynthesis of cytolysin is fairly advanced, 
many of the details of its production, as well as the precise mechanism by which it contributes to the 
pathogenesis of infection, are not well known. Hypothetically, the ability to lyse intestinal epithelial 
cells may allow E. faecalis to access the blood stream in order to travel to and colonize distant sites, 
such as the heart valve. Additionally, the ability to lyse mouse neutrophils and macrophages might 
contribute to immune evasion [44]. Other E. faecalis products, such as gelatinase and capsular 
polysaccharides, have been shown to help the bacteria to circumvent host immunity [55,56], but the 
precise role that the cytolysin might play in immune evasion is still unknown. 
3. Cytolysin Structure and Function 
3.1. Overview of the Cytolysin 
A general scheme for cytolysin production, processing, secretion, and regulation is shown in Figure 1. 
Enterococci produce a wide array of bacterocins, but the cytolysin is the only well characterized 
lantibiotic produced by E. faecalis [57]. Cytolysin production is a variable trait among E. faecalis Toxins 2013, 5  899 
 
 
isolates [16,52,58]. Among cytolysin-producing strains, the operon is either chromosomally-encoded 
within a 150-kilobase pathogenicity island (PAI) [43,59,60], or on a conjugative, pheromone-responsive 
plasmid, such as pAD1 [61–63]. The cytolysin operon consists of six genes related to toxin 
biosynthesis, as well as two divergently transcribed genes encoding regulatory proteins [41,64–67] 
(Figure 1A). In the inactive state, the cytolysin repressor protein CylR2 binds to the PLys (PL)  
promoter [68]. Low-level transcription of the operon is believed to result in basal production of a small 
amount of the cytolysin subunits [67]. Autoinduction via quorum sensing in the presence of target cells 
triggers an inferred change in the binding of the cytolysin promoter by the CylR2 protein, resulting in 
high-level expression of the cytolysin operon [67].  
Figure 1. E. faecalis cytolysin expression. (A) Cytolysin operon in the inactive and active 
states. In the inactive state, CylR2 binds to the PLys (PL) promoter [68]. Autoinduction  
via quorum sensing triggers an inferred change in the binding of the cytolysin promoter by  
the CylR2 protein, resulting in high-level expression of the cytolysin operon [67].   
(B) Cytolysin processing and secretion. Large and small subunits are post-translationally 
modified by CylM [65], secreted and trimmed by CylB [41], and further processed by 
CylA [64]. (C) Cytolysin activity, in the absence and presence of target cells. In the 
absence of target cells the subunits form inactive and insoluble multimeric complexes. In 
the presence of target cells they coordinate to form a pore in the target cell membrane [71]. 
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The functional cytolysin toxin consists of large and small subunit oligopeptides, encoded by the 
genes cylLL and cylLS, respectively [64] (Figure 1B). CylLL and CylLS primary translation products 
undergo extensive post-translational modification, including dehydration of serine and threonine 
residues, and subsequent formation of intramolecular lanthionine and methyllanthionine bridges 
between these dehydrated residues and nearby cysteine thiol groups within each subunit [69,70]. 
Dehydration of the toxin subunits in the initial modification step is inferred to be catalyzed by   
the CylM protein [65]. The ATP-binding cassette (ABC) transporter CylB secretes and trims the 
CylM-modified peptides CylLL
* and CylLS
* [41], resulting in externalization of CylLL’ and CylLS’ 
subunits. These trimmed and secreted subunits are further processed by the CylA serine protease to 
generate the active toxin subunits CylLL” and CylLS” [64,69]. The final gene in the cytolysin operon is 
cylI, which encodes the CylI immunity protein, a transmembrane protein of unknown function that 
confers self-protection to cytolysin-producing cells [66].  
In the absence of target cells, CylLL” and CylLS” strongly associate to form inactive and insoluble 
multimeric complexes. However, when target cells are present the subunits interact, presumably to 
form a pore in the target cell membrane [71] (Figure 1C). The large subunit CylLL” has a greater 
affinity for the target cell membrane than the small subunit, which in the presence of a target cell is 
believed to result in a transient accumulation of excess free CylLS”, generating a quorum   
sensing autoinduction signal that triggers release of CylR2 and high level expression of the cytolysin  
operon. The CylLS” induction signal is believed to be transmitted in some way via the cell surface  
protein CylR1 [67]. 
3.2. Cytolysin Structural and Molecular Properties  
The E. faecalis cytolysin components CylLL and CylLS have been classified as Type-A, pore-forming 
lantibiotics [72], and more recently as two-component, Class II lantibiotics [70]. Lantibiotics are 
complex polycyclic antimicrobial peptides, which are ribosomally synthesized by Gram-positive 
bacteria and are characterized by the presence of lanthionine and methyllanthionine bridges between 
dehydrated serine and threonine residues and cysteine thiols. Lantibiotics have extremely varied 
structures and functions, but they are all characterized by undergoing extensive post-translational 
modification and possessing either antibiotic or mophogenic activities [70]. Cytolysin appears to be 
unique among lantibiotics, in that it can lyse other bacteria as well as erythrocytes and other eukayotic 
cells [73]. The cytolysin subunits possess stretches of identity within the primary translation products, 
which likely target them through the same maturation pathways. They also show limited identity, but 
different bridging patterns, to beta-peptides (also called LanA2 peptides) of the two-component 
lantibiotics lacticin 3147 from Lactococcus lactis [74], and haloduracin from Bacillus halodurans [75].  
The positions of lanthionine linkages within the CylLL” and CylLS” peptides have recently   
been established [76] (Figure 2). Following ribosomal synthesis, the cytolysin subunit prepropeptides  
of 63 (CylLS) and 68 (CylLL) amino acids are modified post-translationally in the cytoplasm   
through reactions which are inferred to be catalyzed by CylM [65,72]. First, dehydration yields   
2,3-didehydroalanine (Dha) from serine, and (Z)-2,3-didehydrobutyrine (Dhb) from threonine [70]. 
Then, neighboring intrapeptide cysteine residues make a nucleophilic, Michael addition to the 
dehydrated side chains, resulting in thioether bonds between the Dha (or Dhb) and cysteine side chains, Toxins 2013, 5  901 
 
 
creating the unusual amino acids lanthionine (when serine is the precursor) or methyllanthionine (when 
threonine is the precursor). Interestingly, the mature cytolysin peptides appear to adopt a unique 
stereochemistry, with CylLL” containing two lanthionine bridges in the unusual LL configuration, and 
CylLS” containing one [76]. Virtually all previously characterized lantibiotics contain bridges in the 
DL configuration. The functional consequence of this stereochemistry is currently unknown. The 
three-dimensional structures of the cytolysin peptides are also currently unknown, but recent advances 
in heterologous production of the subunits in E. coli will likely facilitate their determination [76]. 
Figure 2. Sequences and structures of the E. faecalis cytolysin subunits. (A) Primary 
amino acid sequences of the cytolysin subunits CylLL and CylLS. Arrows indicate sites of 
proteolytic cleavage by CylB and CylA [69], and brackets show the positions of 
lanthionine and methyllanthionine bridges. (B) Structures of the processed mature 
cytolysin subunits. Image is reproduced with permission from [76]. 
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Following modification of the cytolysin prepropeptides, the CylLL
* and CylLS
* propeptides are 
secreted from the cell by the product of the cylB gene [41]. During secretion, CylB removes 24 amino 
acids from the amino terminus of CylLL
* and 36 amino acids from the amino terminus of CylLS
*. This 
removal is believed to be catalyzed by a cysteine protease domain within CylB [41], and cleavage 
occurs within a nearly identical stretch of 26 amino acids in the otherwise structurally dissimilar 
subunits [69]. Whether all or part of these conserved 26 amino acid leader sequences constitutes a 
trafficking signal for CylM-mediated modification or CylB secretion remains to be explored. 
Precisely how the cytolysin modification enzymes CylM, CylB, and CylA are produced, processed 
and sent to their final destinations is unclear. The E. coli hemolysin A toxin (HlyA) is processed and 
secreted by a type 1 secretion system consisting of the inner membrane protein HlyB, the membrane 
fusion protein HlyD, and the outer membrane protein TolC, which form a continuous but   
transient translocator from the cytosol directly out of the cell to allow for HlyA secretion [77].
Complex natural products, including antibiotics, are also synthesized in processive steps by 
multienzyme megasynthase complexes as large as 2 MDa [78]. Experimental evidence suggests that 
the proteins involved in post-translational modification and secretion of the lantibiotic subtilin might 
also organize into a membrane bound complex [79]. Because of the need for processivity in the 
maturation of the cytolysin prepropeptides [65], it seems possible that CylM, CylB, and CylA may 
similarly be organized in a transmembrane complex that efficiently modifies, secretes and activates 
each subunit, but this remains to be shown.  
3.3. Cytolysin Regulation 
The cytolysin operon contains two promoters; the PL promoter regulates transcription of genes 
related to toxin structure and function (cylLL, cylLS, cylM, cylB, cylA, and cylI), while the PReg (PR) 
promoter overlaps with PL and regulates transcription of the regulatory genes cylR1 and cylR2, which 
are transcribed in the opposite direction from the rest of the operon [67,68] (Figure 1A). In the 
uninduced state, the cytolysin operon is believed to be transcribed at a low level, so that a small 
amount of all system components are available to respond to the presence of target cells when the need 
arises [67]. When target cells are present, the large subunit CylLL” preferentially binds to cell 
membranes with greater affinity than the small subunit CylLS”, leading to a transient accumulation of 
free small subunit in solution [71]. Once the concentration of free CylLS” exceeds a threshold, it 
induces transcription of the cytolysin operon from the PL promoter, presumably through altered 
association or dissociation of the CylR2 protein from the promoter region. The crystal structure of 
CylR2 was solved and the precise nature of its binding to PL has been determined in vitro [68]. It is 
also known that CylR1, a suspected membrane protein, is required for induction of the cytolysin 
operon [67]. However, the precise mechanism of how the accumulation of extracellular CylLS” is 
transmitted to intracellular CylR2, as well as the role of CylR1 in transmitting this signal, are not 
currently understood.  
While it appears that the genes within the cytolysin operon are transcribed polycistronically, and 
that the operon contains at least two promoters, there is some experimental evidence to suggest that 
transcription may be more complex. Based on the behavior of transposon insertion mutants, the final 
two genes within the cytolysin operon, cylA and cylI, were originally thought to be transcribed Toxins 2013, 5  903 
 
 
independently from the rest of the operon [64,66]. However, promoter elements besides PL and PR 
have yet to be identified. In the active state, transcripts from cylLL and cylLS are far more abundant 
than transcripts of any other cytolysin components, possibly due to a stem-loop structure between 
cylLL and cylM that may form a conditional terminator element [80]. Prior experiments that focused on 
quantifying transcription of the various cytolysin operon components have relied on PCR-based 
approaches [80], which can artificially simplify the picture through selective amplification of a 
preferred species. Newly developed technologies, such as RNA sequencing (RNA-seq), would allow 
more precise quantification of expression levels of all operon components simultaneously, and can 
distinguish the directionality of transcription as well as transcription initiation from processing sites [81].  
As noted above, CylR1 plays a role in transmitting the induction signal or otherwise facilitates 
induction of cytolysin operon transcription in the presence of target cells [37,67], but the mechanism is 
not obvious. One possibility is that CylR1 and CylR2 may form a novel two-component regulatory 
system that lacks the phosphorelay elements common to classical bacterial two-component systems [82]. 
CylR1 contains three predicted alpha-helical transmembrane domains, and is therefore believed to 
localize to the cell membrane, but this awaits verification. As a membrane protein, CylR1 could sense 
excess CylLS”, either in the environment or in contact with the membrane. Previous models have 
depicted CylR1 associating directly with CylR2, suggesting that a conformational change initiated by 
CylR1 causes CylR2 to dissociate with the PL promoter region [67,83]. Alternately, CylR1 could 
facilitate CylLS” internalization into the cytoplasm, perhaps in association with a cellular oligopeptide 
permease, similar to the mechanism of internalization in E. faecalis for pheromone signaling [84].  
3.4. Toxin Mechanism of Action 
Very little is currently known regarding the nature of the interaction between cytolysin toxin 
subunits, either in the presence or the absence of target cells. The large subunit CylLL” binds to target 
cells with about a seven-fold greater affinity than CylLS” [71]. Interestingly, the immediate precursors 
of the active toxin subunits, CylLL’ and CylLS’, are only six amino acids longer than the fully mature 
subunits, yet these precursors do not detectably associate with each other, and have no detectable 
hemolytic activity [69]. This suggests that the amino terminus of the fully processed toxin subunits is 
instrumental in their association with membranes and into polymers.  
Exactly how the CylLL” and CylLS” subunits compromise target cell membranes leading to lysis is 
unclear, but is likely to bear some similarity to pore formation by the well-studied lantibiotics nisin and 
lacticin 3147, both produced by Lactococcus lactis [85,86]. Nisin forms pores via a multi-step process 
involving: (1) binding to the bacterial cell wall precursor molecule lipid II; and (2) reorientation of 
nisin molecules from parallel to perpendicular to the membrane surface [87]. The amino-terminal rings 
of nisin bind to lipid II, and the carboxy-terminus interacts with the lipid bilayer of the target bacterial 
cell. Accumulation of lipid II and nisin in this way results in a pore formed by four lipid II and eight 
nisin molecules in an unknown structural arrangement [88]. Pore formation by lacticin 3147, a   
two-component lantibiotic, also involves multiple steps: (1) the LtnA1 subunit first associates with the 
membrane; (2) it forms a complex with the LtnA2 subunit in a 1:1 stoichiometry; and (3) LtnA2 in the 
complex then enters the membrane and forms a pore [89]. Whether the cytolysin subunits interact in a 
similar way, as well as their stoichiometry, remains to be determined. Toxins 2013, 5  904 
 
 
Target cell surface receptor, or cell surface receptors, that enable cytolysin-mediated lysis are 
unknown. Cytolysin is unique among lantibiotics in its ability to lyse a broad range of cells, including 
bacteria, various mammalian erythrocytes, and other eukaryotic cells [90]. If there is a specific 
receptor, it would have to be highly conserved across widely divergent kingdoms. As noted above, 
nisin and many other lantibiotics use lipid II as a docking molecule [91,92]. This could be a possible 
candidate for cytolysin targeting of bacteria, but this would invoke different mechanisms for 
prokaryotic and eukaryotic cell lysis. A higher membrane phosphatidylcholine content has been found 
in those erythrocytes that are most susceptible to lysis by cytolysin [34], and both sphingomyelin and 
phosphatidylcholine inhibit the lysis of horse erythrocytes by cytolysin [44]. Finally, cytolysin activity 
could be due to general membrane properties, with susceptibility at least in part attributable to the 
absence of an inhibitor on the target cell surface, such as lecithin [39].  
The way in which cytolysin-producing cells are protected from self-lysis, and how immunity is 
transferred between cells, also are not well understood. Other lantibiotic-producing bacteria are 
protected from self-lysis by immunity proteins and/or ABC transporters that serve to decrease the local 
concentration of the lantibiotic [93,94]. In E. faecalis, the immunity factor CylI, an apparent 
transmembrane protein with possible zinc metalloprotease activity, was shown to be necessary and 
sufficient to confer protection from cytolysin-mediated bacterial cell death [66]. It is unknown whether 
CylI interacts with and/or cleaves one or both cytolysin subunits, but it seems possible that CylI could 
prevent pore formation by cleaving subunits that attempt to embed within the producer cell membrane, 
or by cleaving proteinaceous target cell receptors, should they exist. Because the cytolysin operon is 
encoded on transmissible plasmids and a mobile pathogenicity island, an important unanswered 
question remains as to how the operon encoding the cytolysin is transferred from an immune-producing 
cell to a susceptible recipient without first killing the recipient. One possible explanation for recipient 
cell protection might be the need for high bacterial cell levels to induce cytolysin expression [67]. 
Perhaps the pheromone quorum signaling pathway involved in pAD1 transfer is triggered at lower cell 
densities, before the threshold for derepression of cytolysin expression is reached. 
3.5. Biological Role of Cytolysin 
Many studies of the E. faecalis cytolysin are motivated by findings that this molecule exacerbates 
infection in humans and model systems [22,43,51]. However, because of the relative rarity of   
E. faecalis infection in comparison to its abundance as a commensal in the GI tract of diverse animals, 
it seems likely that this toxin evolved for a more common purpose, where positive selection is more 
likely to apply. For a commensal microbe that is dependent upon its host (and the microbial 
community that the host supports) to fulfill its auxotrophies, it seems probable that selection for the 
cytolysin occurred in an environment that was mutually beneficial to both E. faecalis and its host. 
Possible cytolysin activities that could benefit a host might include: providing a defense against 
something that is more harmful (such as an intestinal parasite), acting as a colonization factor, or 
facilitating nutrient acquisition from prokaryotic or eukaryotic sources. Perhaps the bacteriocin activity 
of the cytolysin allows E. faecalis to occupy a novel host niche that non-cytolytic bacteria cannot 
access. The impact that cytolysin production has on the host microbiome has not yet been investigated, 
although recent advances in microbial ecology and metagenomics should be able to readily address Toxins 2013, 5  905 
 
 
this question in humans [95], or other natural hosts [96,97]. Additionally, E. faecalis can incorporate 
exogenous hemin into its cytochromes, and this was found to provide a growth advantage under 
aerobic conditions [11,98]. Perhaps the ability to co-opt extracellular hemin from a host or neighboring 
organism confers a large enough growth advantage to drive the evolution of target cell lysis by cytolysin.  
In addition to possible roles in colonization and nutrient acquisition, the cytolysin appears to 
function at least in part as a signaling molecule that can monitor bacterial population size and probe  
the environment for target cells [83,99]. Cytolysin subunits are produced and secreted into the 
environment, but their relative abundance is also monitored by the producer cell and when target cells 
are close by, the small subunit CylLS” becomes a signaling molecule that induces a change in gene 
expression, turning on production of additional cytolysin subunits [71]. The ability to recognize the 
presence or absence of target cells allows E. faecalis to respond to its environment in a more nuanced 
way, and may contribute to the successful colonization of many different environmental niches. 
4. Conclusions  
The recent evolution of E. faecalis strains that are both hypervirulent and multidrug resistant 
underscores the need for a better understanding of the biology of this important pathogen. The 
cytolysin forms a critical part of this understanding, as it contributes more to infection toxicity than 
any other E. faecalis factor studied, and it likely also allows E. faecalis to colonize new ecologies.  
A better understanding of the E. faecalis cytolysin may aid in understanding the biological 
mechanisms of other lantibiotics, as well as deepen our knowledge of how Enterococcus evolved this 
molecule in the first place. Application of the latest genomics-age technologies will certainly shed new 
light on the biology of the E. faecalis cytolysin, and will provide a more complete understanding of the 
structure and function of this important molecule. 
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